| 1 |
33220276 | Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys. | 2021 Feb 5 |
1 |
| 2 |
19922897 | Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects. | 2009 Oct |
1 |
| 3 |
14517707 | Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. | 2003 Nov |
2 |
| 4 |
11160877 | Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. | 2001 Feb |
1 |
| 5 |
10882160 | Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. | 2000 Jun |
2 |
| 6 |
11147507 | Issues important for rational COMT inhibition. | 2000 |
1 |
| 7 |
11147508 | Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. | 2000 |
2 |
| 8 |
9403227 | Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. | 1997 Dec |
1 |
| 9 |
8255368 | Clinical pharmacology of the new COMT inhibitor CGP 28,014. | 1993 Nov |
1 |
| 10 |
7447951 | Benserazide and carbidopa as substrates of catechol-O-methyltransferase: new mechanism of action in Parkinson's disease. | 1980 Dec 1 |
1 |
| 11 |
890572 | Competitive inhibition of catechol O-methyltransferase by RO-4-4602. | 1977 Jul |
3 |